Benitec Biopharma Limited (BNTC) – What Are Analysts Thinking About This Stock?

Benitec Biopharma Limited (NASDAQ:BNTC) has received an average rating of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $24.00.

Several research analysts have recently issued reports on BNTC shares. HC Wainwright reissued a “buy” rating on shares of Benitec Biopharma in a research report on Monday, September 28th. Citigroup restated a “market outperform” rating on shares of Benitec Biopharma in a research report on Tuesday, October 6th. Wedbush lifted their price target on Benitec Biopharma from $16.00 to $17.00 and gave the company an “outperform” rating in a research report on Tuesday, September 15th. Wall Street Zen cut Benitec Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Finally, Royal Bank Of Canada upgraded Benitec Biopharma to an “outperform” rating in a report on Tuesday, September 15th.

Benitec Biopharma Stock Performance

Shares of BNTC opened at $8.46 on Friday. Benitec Biopharma has a fifty-two week low of $8.25 and a fifty-two week high of $16.76. The firm has a market cap of $295.08 million, a price-to-earnings ratio of -8.63 and a beta of 0.25. The firm has a 50 day moving average price of $11.36 and a 200-day moving average price of $11.78.

Benitec Biopharma (NASDAQ:BNTC) last released its quarterly earnings data on Monday, September 14th. The biotechnology company reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26). As a group, equities research analysts predict that Benitec Biopharma will post -1.31 earnings per share for the current year.

Institutional Trading of Benitec Biopharma

Institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in Benitec Biopharma by 18.7% during the 2nd quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 1,256 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Benitec Biopharma by 43.3% in the 1st quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock worth $185,000 after buying an additional 5,251 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Benitec Biopharma in the first quarter worth $186,000. Bank of New York Mellon Corp grew its holdings in shares of Benitec Biopharma by 37.6% in the first quarter. Bank of New York Mellon Corp now owns 43,489 shares of the biotechnology company’s stock worth $463,000 after acquiring an additional 11,877 shares during the period. Finally, AWM Investment Company Inc. bought a new stake in shares of Benitec Biopharma in the second quarter worth $2,515,000. 52.19% of the stock is owned by hedge funds and other institutional investors.

About Benitec Biopharma

Benitec Biopharma Limited (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines for chronic and potentially life-threatening diseases. The company’s work is based on DNA-directed RNA interference (ddRNAi), a gene-silencing technology designed to produce sustained suppression of disease-causing genes within targeted cells.

Benitec’s lead investigational product is BB-301, an adeno-associated virus gene therapy being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive difficulty swallowing and weakness of the eyelid and throat muscles.